LY 3016859

Drug Profile

LY 3016859

Alternative Names: LY3016859; TGF-alpha/epiregulin monoclonal antibody

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Monoclonal antibodies; Uroprotectives
  • Mechanism of Action Epidermal growth factor inhibitors; Immunomodulators; Transforming growth factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic nephropathies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetic-nephropathies(In volunteers) in United Kingdom (SC)
  • 01 Aug 2015 Eli Lilly completes a phase I/II trial for Diabetic nephropathies in USA, United Kingdom & Bulgaria (NCT01774981)
  • 27 Mar 2013 Phase-I/II clinical trials in Diabetic nephropathies in Bulgaria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top